{
    "name": "icosapent",
    "comment": "Rx",
    "other_names": [
        "Vascepa"
    ],
    "classes": [
        "Lipid-Lowering Agents",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/vascepa-icosapent-999764",
    "pregnancy": {
        "common": [
            "Available data from published case reports and the pharmacovigilance database on the use in pregnant women are insufficient to identify a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In animal reproduction studies in pregnant rats, nondose-related imbalances for some minor developmental findings were observed with oral administration of icosapent ethyl during organogenesis at exposures that were equivalent to the clinical exposure at the human dose of 4 g/day, based on body surface area comparisons"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Lactation"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to drug or any of its components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Associated with increased risk of atrial fibrillation or atrial flutter requiring hospitalization compared with placebo (3% vs 2%)",
                "Contains ethyl esters of the omega-3 fatty acid, eicosapentaenoic acid (EPA), obtained from the oil of fish; unknown whether patients with allergies to fish and/or shellfish are at increased risk of an allergic reaction",
                "Use associated with increased risk of bleeding; incidence is greater if taking concomitant antithrombotic medications (eg, aspirin, clopidogrel, or warfarin) "
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time; bleeding time reported in those studies has not exceeded normal limits and did not produce clinically significant bleeding episodes",
                        "Monitor patients receiving icosapent with anticoagulants and/or antiplatelet agents for bleeding"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abciximab",
            "description": {
                "common": "icosapent, abciximab.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anagrelide",
            "description": {
                "common": "icosapent, anagrelide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "icosapent, antithrombin alfa.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "icosapent, antithrombin III.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "argatroban",
            "description": {
                "common": "icosapent, argatroban.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "icosapent, aspirin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "icosapent, aspirin/citric acid/sodium bicarbonate.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "icosapent, bivalirudin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cilostazol",
            "description": {
                "common": "icosapent, cilostazol.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "icosapent, clopidogrel.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabigatran",
            "description": {
                "common": "icosapent, dabigatran.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dalteparin",
            "description": {
                "common": "icosapent, dalteparin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desirudin",
            "description": {
                "common": "icosapent, desirudin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dipyridamole",
            "description": {
                "common": "icosapent, dipyridamole.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "icosapent, enoxaparin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eptifibatide",
            "description": {
                "common": "icosapent, eptifibatide.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "icosapent, fondaparinux.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "heparin",
            "description": {
                "common": "icosapent, heparin.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prasugrel",
            "description": {
                "common": "icosapent, prasugrel.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protein C concentrate",
            "description": {
                "common": "icosapent, protein C concentrate.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "icosapent, rivaroxaban.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "icosapent, ticagrelor.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ticlopidine",
            "description": {
                "common": "icosapent, ticlopidine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tirofiban",
            "description": {
                "common": "icosapent, tirofiban.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "icosapent increases effects of warfarin by anticoagulation. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Bleeding event",
            "percent": "12"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "3"
        },
        {
            "name": "Peripheral edema",
            "percent": "3"
        },
        {
            "name": "Constipation",
            "percent": "3"
        },
        {
            "name": "Gout",
            "percent": "3"
        },
        {
            "name": "Atrial fibrillation or flutter",
            "percent": "3"
        },
        {
            "name": "Serious bleeding event",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Blood TG increased",
            "percent": null
        },
        {
            "name": "Abdominal discomfort",
            "percent": null
        },
        {
            "name": "Pain in extremities",
            "percent": null
        }
    ]
}